

18 March 2025

Prof. Bruno Sepodes
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Subject: Withdrawal of Insulin Human Rechon, 100 IU/ml, solution for injection in cartridge
– EMEA/H/C/006011/0000

Dear Prof. Bruno Sepodes,

For the withdrawal of initial marketing authorisation applications

I would like to inform you that, at this point of time, Rechon Life Science AB has taken the decision to withdraw the application for Marketing Authorisation of Insulin Human Rechon, 100 IU/ml, solution for injection in cartridge, which was intended to be used for treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.

This withdrawal is based on the following reason:

Due to business reasons, with agreement of our API supplier - Tonghua Dongbao Pharmaceutical Co., Ltd., Rechon Life Science AB has decided to discontinue this application.

We reserve the right to make further Marketing Authorisation Application submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Yours sincerely,

